NCT04759781Active, not recruiting
MElanoma Research Lymph Node Prediction Implementation National_001
A Prospective Registry Study of a Primary Melanoma Gene-signature to Predict Sentinel Node (SN) Status and Determine Its Prognostic Value for More Accurate Staging of SN-negative Melanoma Patients.
Source: ClinicalTrials.gov · Last updated 23 Apr 2026
Brief summary (registry, in English)
MERLIN\_001 is a prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and to determine its prognostic value for more accurate staging of SN-negative melanoma patients.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 1820 (estimated)
- First submitted
- 15 Feb 2021
- Start date
- 25 Aug 2021
- Primary completion date
- 28 Jun 2024
- Lead sponsor
- SkylineDx
- Diseases
- Melanoma
- NCT number
- NCT04759781
What you commit to
- Study type: Observational
- Planned participants: 1820
- From 25 Aug 2021 to the primary completion date, 28 Jun 2024
- 9 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any prior or concurrent primary invasive melanoma mapping to the same draining lymph node basin(s).
- Documented history of another (prior or concurrent) primary invasive melanoma of T1b or greater at any site within the last 5 years.
- Previous surgery in or radiation therapy to the draining lymph node basin(s) of the current primary melanoma.
Other illness
- Distant metastatic disease (M1a,b,c,d) clinically present at primary diagnosis
- Ocular, vulvar, perianal or mucosal melanomas or melanocytic tumors of uncertain malignant potential (MELTUMP) or atypical Spitz tumors.
Other
- Full primary melanoma pathology report unavailable.
- Documented clinically apparent nodal metastases at diagnosis.
Who the study is looking for
- Newly diagnosed patients with invasive malignant melanoma of the skin (AJCC 8th edition staging guidelines) elected to undergo sentinel lymph node biopsy per the treating physician's recommendation.
- Male or female, age ≥18 years.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Michigan Coordinator of this site? Confirm its status | Ann Arbor | United States | Unknown status |
| Emory University School of Medicine Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
| Duke University Coordinator of this site? Confirm its status | Durham | United States | Unknown status |
| University of Kentucky Coordinator of this site? Confirm its status | Lexington | United States | Unknown status |
| University of Louisville Coordinator of this site? Confirm its status | Louisville | United States | Unknown status |
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| Mayo Clinic Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
| Huntsman Cancer Institute Coordinator of this site? Confirm its status | Salt Lake City | United States | Unknown status |
| Moffitt Cancer Center Coordinator of this site? Confirm its status | Tampa | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.